When COFEPRIS Rejects Your Supplement Label: The 6 Most Common Reasons and What to Fix Before Resubmitting

The "Mexican FDA" just rejected your label. Now what?

COFEPRIS label rejection reasons for supplements are specific, documented, and almost entirely avoidable. If you're a US brand that shipped product samples to a Mexican distributor, built out your Amazon MX listings, and then got a rejection notice you can barely translate, you're not alone. This happens to founders who assumed that an FDA-compliant label was close enough. It isn't. Not even close.

The Mexican regulatory framework for dietary supplements runs on different logic than the US system. COFEPRIS, the federal agency that governs health product approvals in Mexico, does not recognize your Certificate of Free Sale as a substitute for its own requirements. It doesn't care that you passed NSF certification. And it will reject your label submission for reasons that feel bureaucratic and arbitrary until you understand the underlying rules.

This post breaks down the six most common rejection triggers, what each one actually means, what it costs you in time and money, and what to fix before you resubmit. We also cover a few things Mexican regulatory consultants won't tell you upfront because they'd rather bill for the surprises.

---

What you need to know before you resubmit anything

80% of first-time supplement label rejections from US brands trace back to the same cluster of errors. That number comes from consultants who work COFEPRIS submissions daily, and it matches what our team at Datahooks sees when scanning listings on Amazon MX and MercadoLibre against regulatory requirements.

The core problem is a classification mismatch. In the US, a supplement is a supplement. In Mexico, the same product might be classified as a suplemento alimenticio (dietary supplement), a medicamento herbolario (herbal medicine), or a remedio herbolario (traditional herbal remedy). Each category has different labeling requirements, different allowed claims, and a different approval pathway. Getting this wrong at the start means every other piece of your label is built on the wrong foundation, and no amount of formatting fixes will save you.

Confirm your classification before you touch anything else. If you're not sure how Mexico classifies your product, read our breakdown on supplement vs. medicine classification in Mexico before opening your label file.

Once classification is confirmed, the six failure points below are what most submissions hit. Listed in order of frequency, not severity.

---

Reason 1: The qualitative-quantitative formula is missing or formatted wrong

Every rejected COFEPRIS submission we've reviewed has a problem with the fórmula cuali-cuantitativa (QQ formula). This is your ingredients list, but not the way you think about it from US experience.

In the US, your supplement facts panel lists active ingredients with amounts per serving. COFEPRIS requires the QQ formula as a separate document, submitted alongside the label, not on it, that discloses every ingredient, active and inactive, including excipients, with precise quantities per dosage unit. Not per serving. Per unit.

If your gummy contains titanium dioxide as a colorant, COFEPRIS wants that disclosed quantitatively. If your capsule shell is gelatin or hydroxypropyl methylcellulose, it appears with its exact amount per capsule. This trips up US brands because most founders have never seen their contract manufacturer's full batch formula, they've only seen the supplement facts panel their brand manager designed.

The fix: get your contract manufacturer to provide the full batch formula with every ingredient including inactive components, expressed per dosage unit. Then have a Mexican regulatory consultant cross-check every ingredient name against the COFEPRIS permitted list. "Vitamin C" and "ascorbic acid" are not interchangeable in a COFEPRIS submission, the naming convention matters and it's not intuitive.

Also worth checking before you spend money on a label translation: some ingredients that are unremarkable in the US are banned or restricted in Mexico entirely. See the ingredients banned in Mexico your formulator doesn't know about.

---

Reason 2: Health claims that are legal in the US but prohibited in Mexico

Mexican law prohibits structure-function claims on supplement labels, and that single rule eliminates most of the marketing language US brands treat as standard. Full stop.

"Supports immune health" is a structure-function claim. So is "promotes healthy digestion," "helps maintain energy levels," and "supports cognitive function." These are standard US supplement marketing language. COFEPRIS rejects them. What's permitted on a suplemento alimenticio label is limited to nutrient content claims that do not imply a health benefit and do not reference a disease, and even those are constrained.

Here's the part that catches brands who think this is a label-redesign problem: if your US-version product arrives at a Mexican warehouse with prohibited claims on the label, and customs or COFEPRIS spot-checks that shipment, you're looking at product seizure, not a label revision request. Mexico requires compliant Spanish-language labels before products enter commerce, not after you've started selling. Brands that compress their launch timeline by shipping inventory early are betting on not getting checked. Some of them lose that bet.

NOM-051 governs general food and supplement labeling in Mexico. Our complete NOM-051 labeling guide is the right starting point if you haven't worked through how it applies to your specific product.

---

Reason 3: The aviso de funcionamiento was never filed, or was filed under the wrong entity

Filing an aviso de funcionamiento must precede any label submission, and skipping it causes your submission to be returned without review before anyone at COFEPRIS has looked at a single page. It's the operational notice that tells COFEPRIS you exist as a business engaged in health product commerce in Mexico. Filing it under an entity that doesn't match your import documentation produces the same result.

The aviso de funcionamiento is free to file and doesn't require a lawyer. But it does require:

• A Mexican legal entity (or a Mexican-resident responsible party called the Responsable Sanitario)
• A valid RFC (your company's Mexican tax ID)
• An eFirma (Mexico's digital signature, formerly called FIEL)
• A physical address in Mexico where product operations occur

For US brands without a Mexican entity, this is the first real structural decision: do you form a Mexican subsidiary, work through a distributor who files under their entity, or use a third-party operations partner? Each path has different timeline and cost implications, and the choice you make here affects what happens if you ever want to change distributors.

The detailed mechanics of this filing, including what "operations address" actually means when you warehouse through a 3PL, are covered in our aviso de funcionamiento explainer.

If you skipped this step and went straight to label submission, that's your rejection. Fix the entity structure first. Everything else waits.

---

Reason 4: NOM-051 warning seals applied incorrectly, or missing entirely

NOM-051's octagonal warning seals are mandatory on any food or supplement that exceeds threshold levels for calories, sodium, saturated fat, added sugars, or other regulated nutrients, and the threshold starts at 275 kcal per 100g for solid products. The seals must meet precise size, placement, color, and typography specifications. Getting one wrong, wrong size, wrong placement zone, wrong typeface, counts as a labeling violation and triggers rejection.

The thresholds are stricter than most US brands expect:

Two seals that routinely surprise US supplement brands: "contains caffeine" and "contains sweeteners" are mandatory disclosures regardless of amount, they're not threshold-based. Any product with stevia, sucralose, erythritol, or added caffeine gets the seal. Gummy vitamins, flavored protein powders, pre-workouts, and sleep supplements with melatonin blends will likely trigger multiple seals.

Phase 3 of NOM-051 implementation, which covers smaller unit sizes, is scheduled for 2027-2028. If you're reformulating anyway, it's worth getting ahead of it. The NOM-051 Phase 3 timeline and implications for US brands explains what's changing and what it costs to get there early versus being forced to retrofit.

On the demand side: the supplements market intelligence report shows category growth that justifies the labeling investment for any brand already doing $5M+ in US revenue. The gummy vitamin segment alone is growing at 20%+ CAGR according to our gummy vitamin category analysis.

---

Reason 5: The análisis bromatológico doesn't match the label

A bromatological analysis, the lab report that validates your nutrition facts, is required for COFEPRIS supplement approval, and any discrepancy between the lab results and your declared nutrition facts panel triggers rejection. The problem usually isn't fraud. It's that the US-version nutrition facts were generated from a different batch, or a formulation tweak happened without updating the analysis, or the lab that ran the US analysis used different methodology than COFEPRIS requires. We've seen brands where the protein content on the US label was calculated using one nitrogen conversion factor and the Mexican lab came back with a different number, not because the product changed, but because the methodology did.

COFEPRIS requires the análisis bromatológico to be conducted by an accredited Mexican laboratory, or a laboratory whose methodology COFEPRIS specifically recognizes. An FDA-registered US lab report is not automatically accepted.

Budget for a Mexican lab analysis early, before label design is finalized, not after. If your formula has changed since the last analysis, you need a new one. If you're working with a US co-manufacturer, get them to send product samples to a COFEPRIS-recognized lab as part of your pre-submission checklist, not as an afterthought when you're three weeks from your launch target.

---

Reason 6: The Responsable Sanitario doesn't exist, or isn't properly registered

Every supplement product sold in Mexico must have a named Responsable Sanitario, and if the submission lists someone who isn't properly registered with COFEPRIS under their professional license number, rejection is automatic. This is a licensed professional, typically a chemist, biologist, or pharmacist, who is legally accountable to COFEPRIS for the product's safety and compliance. If the entity on the label doesn't match the entity on the COFEPRIS registration, the result is the same.

For US founders, this requirement has no equivalent in the FDA framework, which makes it easy to underestimate. The FDA doesn't require a named individual to stake their professional license on your product. COFEPRIS does. That person can face regulatory consequences personally if your product causes harm.

Options for US brands:

1. Hire a Mexican regulatory consultant who also serves as Responsable Sanitario (common, but creates a conflict of interest, they're less likely to flag problems with their own advice)
2. Retain a specialized Responsable Sanitario service through a Mexican regulatory firm
3. Structure your distributor agreement so the Mexican distributor's Responsable Sanitario covers your products

Option 3 sounds like the easy path. It works until you want to change distributors. The COFEPRIS registration is tied to the entity holding the Responsable Sanitario, which means a distributor transition can require restarting the registration process from scratch. We've watched brands lose four months to a distributor switch they didn't anticipate when they signed the original agreement.

If you're weighing the distributor path against a direct entity structure, see our vs. hiring a distributor comparison before signing anything.

---

How it works in practice: the COFEPRIS supplement label approval timeline

The theoretical approval timeline for a COFEPRIS supplement label submission is 30 business days from the date of a complete submission. Build your inventory and launch plan around that number and you will be wrong.

That timeline matters for inventory planning. A US brand that imports product into Mexico before COFEPRIS label approval is either holding unlabeled inventory in a bonded warehouse or taking a compliance risk by selling before approval. Neither is comfortable, and the storage fees on non-sellable inventory add up fast.

The import mechanics, including the T1 courier exemption for test shipments and the IOR structure for real volume, are covered in what IOR approval actually looks like for your first Mexico shipment.

---

Costs and timeline: what resubmission actually costs you

A first COFEPRIS submission runs $4,600 to $13,800 USD per SKU in direct costs alone, before you account for the opportunity cost of a delayed launch. Here's how to think about both.

The opportunity cost is harder to put a number on and easier to ignore until it's too late. If you planned to launch on Amazon Mexico in Q2 and a label rejection adds four months to your timeline, you've lost the Q2 and Q3 selling seasons. For sleep and stress supplements or sports nutrition, that's real money tied to real seasonality.

The honest math: for a brand doing $5M+ in US supplement revenue, the total cost to get one SKU properly through COFEPRIS is $5,000-$15,000 and 3-6 months the first time. That's real money and real time. It's also a one-time structural investment. Once you have the entity, the Responsable Sanitario, the aviso de funcionamiento, and one approved label as a template, subsequent SKUs move faster and cost less.

For brands wondering whether Mexico justifies the effort at all, the 65 million buyers, one entity post provides the demand-side context. The Amazon MX unit economics by category are in this breakdown.

---

COFEPRIS label rejection mistakes that make a second one likely

Getting rejected once is expensive. Getting rejected twice on the same SKU for different reasons means your pre-submission process is broken, and the second rejection typically costs an additional $2,300 to $6,300 USD per SKU on top of what you already spent.

Fixing only what COFEPRIS flagged is the most common mistake. COFEPRIS review is not exhaustive. A deficiency notice might flag your missing QQ formula without mentioning that your health claims violate Article 216 of the General Health Law. You fix the QQ formula, resubmit, and get rejected for the claims issue. A proper pre-submission review catches everything, not just whatever the reviewer happened to flag first.

Using the wrong entity on the resubmission is another frequent problem. If your company structure changed between submissions, or if the original was filed under a distributor you're no longer working with, the entity mismatch alone causes rejection. This is more common than it sounds, especially for brands that change distribution partners mid-process.

Assuming the Mexican lab analysis is still valid trips up brands that move slowly. Lab analyses have a regulatory shelf life. If your original analysis is more than 12 months old and you're resubmitting, get a new one. Don't find out it's expired after COFEPRIS tells you.

Translating the US label instead of redesigning it produces a rejection that looks exactly like the first one. A translated US label is still a US label. The information hierarchy, font sizes, placement zones, and panel structure of a COFEPRIS-compliant label are different from FDA requirements.

Not checking against current NOM-051 requirements catches brands that produced compliant artwork before October 2023. NOM-051 has been amended since its 2020 implementation. Verify against current requirements before resubmitting. If you're uncertain how NOM-051 amendments interact with reformulation decisions, this food and beverage reformulation analysis covers the structural logic even though it's framed around food brands.

---

What's different if you're selling through MercadoLibre vs. Amazon MX

The COFEPRIS label requirement applies regardless of channel, but Amazon MX has increased COFEPRIS compliance checks on supplement listings since 2023, and listings without evidence of proper COFEPRIS registration are being removed, sometimes without warning. Enforcement reality differs by platform in ways that matter for your launch sequencing.

MercadoLibre historically had lighter enforcement on seller compliance. That's changing as AMVO and regulatory pressure on cross-border e-commerce increases. Selling on MercadoLibre without proper COFEPRIS registration is a short-term strategy with a defined expiration date. How short depends on your category and your visibility, but the direction is clear.

The dominant brand dynamics on Amazon MX supplement categories, including who's winning and why, are in our 7 products you can't sell in Mexico post and the OLLY gummy vitamin market analysis that shows what market share actually looks like in the gummy segment.

For supplement brands specifically, our dedicated supplement brands page outlines the full service context.

---

Next steps before you resubmit

Do these in order. Skipping steps to move faster is how you end up paying for a third submission, and the 7 steps below represent the minimum viable pre-submission checklist based on what COFEPRIS actually reviews.

Step 1: Confirm your product classification. Is it a suplemento alimenticio, a medicamento herbolario, or something else? This determines which regulations apply. If you're unsure, get a classification opinion from a Mexican regulatory professional before doing anything else.

Step 2: Verify your legal structure. Does your aviso de funcionamiento exist and is it filed under the correct entity? Is your Responsable Sanitario properly registered with COFEPRIS? If either answer is no, fix it before touching the label.

Step 3: Audit every ingredient in your QQ formula. Cross-reference against the COFEPRIS permitted ingredient list. If anything isn't on the list or isn't listed under the exact approved name, you have a problem that label redesign won't fix.

Step 4: Eliminate all prohibited claims from your label artwork. Structure-function claims must come off the Mexican version entirely. This is non-negotiable, and it means your Mexican label will not look like your US label. That's fine.

Step 5: Apply NOM-051 warning seals correctly. Run your nutrition facts against the current thresholds. Get artwork produced by a designer who has done COFEPRIS-compliant labels before, not someone adapting your US Illustrator file over a weekend.

Step 6: Get a current Mexican lab analysis. One that's COFEPRIS-recognized, covers all required parameters, and was run on the same formulation you're submitting.

Step 7: Run your final package through a pre-submission review. Either a qualified regulatory consultant or a tool that checks against current COFEPRIS requirements. Not someone who gives your label a quick read and says it looks good.

Before any of that, run your product through the Mexico Scanner tool to get an initial read on where you stand against Mexican regulatory requirements. It's the fastest way to identify which of the six issues above applies to your specific situation before you spend consulting fees finding out.

If you're weighing whether to handle resubmission internally versus working with an operations partner, compare the DIY approach against what structured support actually provides. Most founders who manage COFEPRIS submissions themselves without prior Mexico regulatory experience spend more than they budgeted, take longer than they planned, and get rejected at least once. That's not a knock on the founders, the requirements are genuinely non-obvious and the documentation requirements are dense. It's just the pattern we see.

The Mexico supplement market is worth the work. The regulatory process is the filter that keeps it less crowded than it should be.

---

Ready to build a compliant Mexico launch from the start? The Mexico Launch Blueprint walks through entity structure, COFEPRIS strategy, and channel selection for supplement brands at the $1M-$50M stage.